National Institute on Drug Abuse; Notice of Closed Meetings, 59414 [2011-24660]

Download as PDF 59414 Federal Register / Vol. 76, No. 186 / Monday, September 26, 2011 / Notices Dated: September 20, 2011. Jennifer S. Spaeth, Director, Office of Federal Advisory Committee Policy. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2011–24651 Filed 9–23–11; 8:45 am] National Institute on Drug Abuse; Notice of Closed Meetings National Institutes of Health BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting jlentini on DSK4TPTVN1PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Board of Scientific Counselors, National Advisory Neurological Disorders and Stroke. The meeting will be closed to the public as indicated below in accordance with the provisions set forth in sections 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute of Neurological Disorders and Stroke, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Board of Scientific Counselors, National Institute of Neurological Disorders and Stroke. Date: October 16–18, 2011. Time: 7 p.m. to 11:30 a.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Alan P. Koretsky, PhD, Scientific Director, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, NIH, 35 Convent Drive, Room 6A908, Bethesda, MD 20892, (301) 435–2232, koretskya@ninds.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS). Dated: September 19, 2011 Jennifer S. Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2011–24647 Filed 9–23–11; 8:45 am] BILLING CODE 4140–01–P VerDate Mar<15>2010 17:37 Sep 23, 2011 Jkt 223001 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, I/ START Review Committee. Date: October 14, 2011. Time: 8 a.m. to 8 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Virtual Meeting). Contact Person: Mark Swieter, PhD, Chief, Extramural Activities Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4235, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892–9550, 301–435–1389, ms80x@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, B/ START Review Committee. Date: October 14, 2011. Time: 8 a.m. to 8 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Virtual Meeting). Contact Person: Mark Swieter, PhD, Chief, Extramural Activities Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4235, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892–9550, 301–435–1389, ms80x@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Institutional Research Training Grants (T32). Date: November 3, 2011. Time: 10 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Ritz-Carlton Hotel at Pentagon City, 1250 South Hayes Street, Arlington, VA 22202. Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4245, MSC PO 00000 Frm 00036 Fmt 4703 Sfmt 9990 9550, 6001 Executive Blvd., Bethesda, MD 20892–9550, 301–451–4530, el6r@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, NIDA– K Conflict. Date: November 3, 2011. Time: 5 p.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Ritz-Carlton Hotel at Pentagon City, 1250 South Hayes Street, Arlington, VA 22202. Contact Person: Gerald L. McLaughlin, PhD, Chief, Grants Review Branch and Contracts Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4238, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892–9550, 301–402–6626, gm145a@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Exploring Drugs of Abuse and Transgenerational Phenotypes (R01). Date: November 17, 2011. Time: 9 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: The Westin Washington, DC City Center, 1400 M Street, NW., Washington, DC 20005. Contact Person: Minna Liang, PhD, Scientific Review Officer, Grants Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, Room 4226, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892–9550, 301–435–1432, liangm@nida.nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, NIDA Cutting-Edge Basic Research Awards (CEBRA) (R21). Date: December 2, 2011. Time: 9 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Virtual Meeting). Contact Person: Scott A. Chen, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4234, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892–9550, 301–443–9511, chensc@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: September 20, 2011. Jennifer S. Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2011–24660 Filed 9–23–11; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\26SEN1.SGM 26SEN1

Agencies

[Federal Register Volume 76, Number 186 (Monday, September 26, 2011)]
[Notices]
[Page 59414]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-24660]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
USC, as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable materials, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel, I/START Review Committee.
    Date: October 14, 2011.
    Time: 8 a.m. to 8 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852, (Virtual Meeting).
    Contact Person: Mark Swieter, PhD, Chief, Extramural Activities 
Branch, Office of Extramural Affairs, National Institute on Drug 
Abuse, NIH, DHHS, Room 4235, MSC 9550, 6001 Executive Blvd., 
Bethesda, MD 20892-9550, 301-435-1389, ms80x@nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel, B/START Review Committee.
    Date: October 14, 2011.
    Time: 8 a.m. to 8 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852, (Virtual Meeting).
    Contact Person: Mark Swieter, PhD, Chief, Extramural Activities 
Branch, Office of Extramural Affairs, National Institute on Drug 
Abuse, NIH, DHHS, Room 4235, MSC 9550, 6001 Executive Blvd., 
Bethesda, MD 20892-9550, 301-435-1389, ms80x@nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel, Institutional Research Training Grants (T32).
    Date: November 3, 2011.
    Time: 10 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Ritz-Carlton Hotel at Pentagon City, 1250 South Hayes 
Street, Arlington, VA 22202.
    Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 4245, MSC 9550, 6001 Executive Blvd., 
Bethesda, MD 20892-9550, 301-451-4530, el6r@nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel, NIDA-K Conflict.
    Date: November 3, 2011.
    Time: 5 p.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Ritz-Carlton Hotel at Pentagon City, 1250 South Hayes 
Street, Arlington, VA 22202.
    Contact Person: Gerald L. McLaughlin, PhD, Chief, Grants Review 
Branch and Contracts Review Branch, Office of Extramural Affairs, 
National Institute on Drug Abuse, NIH, DHHS, Room 4238, MSC 9550, 
6001 Executive Blvd., Bethesda, MD 20892-9550, 301-402-6626, 
gm145a@nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel, Exploring Drugs of Abuse and Transgenerational 
Phenotypes (R01).
    Date: November 17, 2011.
    Time: 9 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: The Westin Washington, DC City Center, 1400 M Street, 
NW., Washington, DC 20005.
    Contact Person: Minna Liang, PhD, Scientific Review Officer, 
Grants Review Branch, Office of Extramural Affairs, National 
Institute on Drug Abuse, NIH, Room 4226, MSC 9550, 6001 Executive 
Blvd., Bethesda, MD 20892-9550, 301-435-1432, liangm@nida.nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel, NIDA Cutting-Edge Basic Research Awards (CEBRA) 
(R21).
    Date: December 2, 2011.
    Time: 9 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852, (Virtual Meeting).
    Contact Person: Scott A. Chen, PhD, Scientific Review 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 4234, MSC 9550, 6001 Executive Blvd., 
Bethesda, MD 20892-9550, 301-443-9511, chensc@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: September 20, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-24660 Filed 9-23-11; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.